Triple Negative Breast Cancer (TNBC) is a highly aggressive subtype, accounting for 10–20% of all diagnosed breast cancers, with no targeted therapy available due to the lack of oestrogen and progesterone receptor expression and the absence of HER2 amplification [3]. Here, ERBB2 is linked to breast cancer.